Ching-Hon Pui1, Paola Rebora2, Martin Schrappe3, Andishe Attarbaschi4, Andre Baruchel5, Giuseppe Basso6, Hélène Cavé5, Sarah Elitzur7, Katsuyoshi Koh8, Hsi-Che Liu9, Kajsa Paulsson10, Rob Pieters11, Lewis B Silverman12, Jan Stary13, Ajay Vora14, Allen Yeoh15, Christine J Harrison16, Maria Grazia Valsecchi2. 1. 1 St Jude Children's Research Hospital and University of Tennessee Health Science Center, Memphis, TN. 2. 2 University of Milano-Bicocca, Monza, Italy. 3. 3 University of Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany. 4. 4 St Anna's Children's Hospital and Medical University of Vienna, Vienna, Austria. 5. 5 Robert Debré Hospital and Paris Diderot University, Paris, France. 6. 6 University of Padova, Padova, Italy. 7. 7 Tel Aviv University, Tel Aviv, Israel. 8. 8 Saitama Children's Medical Center, Saitama, Japan. 9. 9 MacKay Memorial Hospital, Taipei, Taiwan. 10. 10 Lund University, Lund, Sweden. 11. 11 Princess Máxima Centre for Pediatric Oncology, Utrecht, the Netherlands. 12. 12 Dana-Farber Cancer Institute/Boston Children's Hospital, Boston, MA. 13. 13 University Hospital Motol and Charles University, Prague, Czech Republic. 14. 14 Great Ormond Street Hospital, London, United Kingdom. 15. 15 National University of Singapore, Singapore. 16. 16 Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne, United Kingdom.
Abstract
PURPOSE: We determined the prognostic factors and utility of allogeneic hematopoietic cell transplantation among children with newly diagnosed hypodiploid acute lymphoblastic leukemia (ALL) treated in contemporary clinical trials. PATIENTS AND METHODS: This retrospective study collected data on 306 patients with hypodiploid ALL who were enrolled in the protocols of 16 cooperative study groups or institutions between 1997 and 2013. The clinical and biologic characteristics, early therapeutic responses as determined by minimal residual disease (MRD) assessment, treatment with or without MRD-stratified protocols, and allogeneic transplantation were analyzed for their impact on outcome. RESULTS: With a median follow-up of 6.6 years, the 5-year event-free survival rate was 55.1% (95% CI, 49.3% to 61.5%), and the 5-year overall survival rate was 61.2% (95% CI, 55.5% to 67.4%) for the 272 evaluable patients. Negative MRD at the end of remission induction, high hypodiploidy with 44 chromosomes, and treatment in MRD-stratified protocols were associated with a favorable prognosis, with a 5-year event-free survival rate of 75% (95% CI, 66.0% to 85.0%), 74% (95% CI, 61.0% to 89.0%), and 62% (95% CI, 55.0% to 69.0%), respectively. After exclusion of patients with high hypodiploidy with 44 chromosomes and adjustment for waiting time to transplantation and for covariables in a Poisson model, disease-free survival did not differ significantly ( P = .16) between the 42 patients who underwent transplantation and the 186 patients who received chemotherapy only, with an estimated 5-year survival rate of 59% (95% CI, 46.5% to 75.0%) versus 51.5% (95% CI, 44.7% to 59.4%), respectively. Transplantation produced no significant impact on outcome compared with chemotherapy alone, especially among the subgroup of patients who achieved a negative MRD status upon completion of remission induction. CONCLUSION: MRD-stratified treatments improved the outcome for children with hypodiploid ALL. Allogeneic transplantation did not significantly improve outcome overall and, in particular, for patients who achieved MRD-negative status after induction.
PURPOSE: We determined the prognostic factors and utility of allogeneic hematopoietic cell transplantation among children with newly diagnosed hypodiploid acute lymphoblastic leukemia (ALL) treated in contemporary clinical trials. PATIENTS AND METHODS: This retrospective study collected data on 306 patients with hypodiploid ALL who were enrolled in the protocols of 16 cooperative study groups or institutions between 1997 and 2013. The clinical and biologic characteristics, early therapeutic responses as determined by minimal residual disease (MRD) assessment, treatment with or without MRD-stratified protocols, and allogeneic transplantation were analyzed for their impact on outcome. RESULTS: With a median follow-up of 6.6 years, the 5-year event-free survival rate was 55.1% (95% CI, 49.3% to 61.5%), and the 5-year overall survival rate was 61.2% (95% CI, 55.5% to 67.4%) for the 272 evaluable patients. Negative MRD at the end of remission induction, high hypodiploidy with 44 chromosomes, and treatment in MRD-stratified protocols were associated with a favorable prognosis, with a 5-year event-free survival rate of 75% (95% CI, 66.0% to 85.0%), 74% (95% CI, 61.0% to 89.0%), and 62% (95% CI, 55.0% to 69.0%), respectively. After exclusion of patients with high hypodiploidy with 44 chromosomes and adjustment for waiting time to transplantation and for covariables in a Poisson model, disease-free survival did not differ significantly ( P = .16) between the 42 patients who underwent transplantation and the 186 patients who received chemotherapy only, with an estimated 5-year survival rate of 59% (95% CI, 46.5% to 75.0%) versus 51.5% (95% CI, 44.7% to 59.4%), respectively. Transplantation produced no significant impact on outcome compared with chemotherapy alone, especially among the subgroup of patients who achieved a negative MRD status upon completion of remission induction. CONCLUSION: MRD-stratified treatments improved the outcome for children with hypodiploid ALL. Allogeneic transplantation did not significantly improve outcome overall and, in particular, for patients who achieved MRD-negative status after induction.
Authors: Charles G Mullighan; Sima Jeha; Deqing Pei; Debbie Payne-Turner; Elaine Coustan-Smith; Kathryn G Roberts; Esmé Waanders; John K Choi; Xiaotu Ma; Susana C Raimondi; Yiping Fan; Wenjian Yang; Guangchun Song; Jun J Yang; Hiroto Inaba; James R Downing; Wing H Leung; W Paul Bowman; Mary V Relling; William E Evans; Jinghui Zhang; Dario Campana; Ching-Hon Pui Journal: Blood Date: 2015-11-02 Impact factor: 22.113
Authors: Denise M Oliansky; Bruce Camitta; Paul Gaynon; Michael L Nieder; Susan K Parsons; Michael A Pulsipher; Hildy Dillon; Thomas A Ratko; Donna Wall; Philip L McCarthy; Theresa Hahn Journal: Biol Blood Marrow Transplant Date: 2011-12-29 Impact factor: 5.742
Authors: Martin Stanulla; Elif Dagdan; Marketa Zaliova; Anja Möricke; Chiara Palmi; Giovanni Cazzaniga; Cornelia Eckert; Geertruy Te Kronnie; Jean-Pierre Bourquin; Beat Bornhauser; Rolf Koehler; Claus R Bartram; Wolf-Dieter Ludwig; Kirsten Bleckmann; Stefanie Groeneveld-Krentz; Denis Schewe; Stefanie V Junk; Laura Hinze; Norman Klein; Christian P Kratz; Andrea Biondi; Arndt Borkhardt; Andreas Kulozik; Martina U Muckenthaler; Giuseppe Basso; Maria Grazia Valsecchi; Shai Izraeli; Britt-Sabina Petersen; Andre Franke; Petra Dörge; Doris Steinemann; Oskar A Haas; Renate Panzer-Grümayer; Hélène Cavé; Richard S Houlston; Gunnar Cario; Martin Schrappe; Martin Zimmermann Journal: J Clin Oncol Date: 2018-03-02 Impact factor: 44.544
Authors: Susana C Raimondi; Yinmei Zhou; Susan Mathew; Sheila A Shurtleff; John T Sandlund; Gaston K Rivera; Frederick G Behm; Ching-Hon Pui Journal: Cancer Date: 2003-12-15 Impact factor: 6.860
Authors: Ching-Hon Pui; Jun J Yang; Stephen P Hunger; Rob Pieters; Martin Schrappe; Andrea Biondi; Ajay Vora; André Baruchel; Lewis B Silverman; Kjeld Schmiegelow; Gabriele Escherich; Keizo Horibe; Yves C M Benoit; Shai Izraeli; Allen Eng Juh Yeoh; Der-Cherng Liang; James R Downing; William E Evans; Mary V Relling; Charles G Mullighan Journal: J Clin Oncol Date: 2015-08-24 Impact factor: 44.544
Authors: Shannon L Maude; Theodore W Laetsch; Jochen Buechner; Susana Rives; Michael Boyer; Henrique Bittencourt; Peter Bader; Michael R Verneris; Heather E Stefanski; Gary D Myers; Muna Qayed; Barbara De Moerloose; Hidefumi Hiramatsu; Krysta Schlis; Kara L Davis; Paul L Martin; Eneida R Nemecek; Gregory A Yanik; Christina Peters; Andre Baruchel; Nicolas Boissel; Francoise Mechinaud; Adriana Balduzzi; Joerg Krueger; Carl H June; Bruce L Levine; Patricia Wood; Tetiana Taran; Mimi Leung; Karen T Mueller; Yiyun Zhang; Kapildeb Sen; David Lebwohl; Michael A Pulsipher; Stephan A Grupp Journal: N Engl J Med Date: 2018-02-01 Impact factor: 91.245
Authors: C-H Pui; D Pei; S C Raimondi; E Coustan-Smith; S Jeha; C Cheng; W P Bowman; J T Sandlund; R C Ribeiro; J E Rubnitz; H Inaba; T A Gruber; W H Leung; J J Yang; J R Downing; W E Evans; M V Relling; D Campana Journal: Leukemia Date: 2016-08-18 Impact factor: 11.528
Authors: David O'Connor; Amir Enshaei; Jack Bartram; Jeremy Hancock; Christine J Harrison; Rachael Hough; Sujith Samarasinghe; Claire Schwab; Ajay Vora; Rachel Wade; John Moppett; Anthony V Moorman; Nick Goulden Journal: J Clin Oncol Date: 2017-11-13 Impact factor: 44.544